CommercialCoverageMedium impact
Lead Testing (CPB 0553, reviewed 2025-11-26)
Aetna·Pediatrics, OB-GYN, Occupational Medicine +2 more·Medical Policy
We identified it
Aug 18, 2026
Summary
Aetna's Lead Testing policy (CPB 0553) clarifies medical necessity criteria for blood lead testing (CPT 83655) across three scenarios: diagnostic testing for symptomatic patients, screening for high-risk pregnant/lactating women, and preventive screening for at-risk children and occupational exposures. The policy explicitly excludes coverage for lead measurement in bone, hair, teeth, or urine, and includes a note regarding re-testing of patients previously tested with recalled Magellan Diagnostics LeadCare analyzers.
Action Required
Immediately: Billing team must implement CPT 83655 coverage rules based on three approved scenarios only: (1) symptomatic patients with clinical signs/symptoms of lead poisoning (document diagnosis codes like T56.0X1A-T56.0X4S, R10.0-R10.9, R11.0-R11.2, R51.0-R51.9, or R53.0-R53.83), (2) pregnant/lactating women with documented lead exposure risk factors per policy appendix (code O26.891-O26.899), and (3) qualifying children per CDC/AAP guidelines with appropriate ICD-10 codes (Z13, F80.0-F89, R62.0-R62.59, G40.001-G40.919, or others listed). Deny claims for CPT 83655 when billed for: routine screening of average-risk pregnant women, lead measurement in bone/hair/teeth/urine, or other indications not meeting criteria. Update claim scrubbing rules in billing software to require one of the approved indication codes. For patients with prior testing using Magellan LeadCare analyzer before May 17, 2017: children under 72 months with prior results <10 mcg/dL and currently pregnant/lactating women may require re-testing per CDC guidance—flag these for provider review. Training: Educate providers and front-desk staff on coverage limitations, particularly that routine screening of asymptomatic pregnant women without risk factors will not be covered. Consequence: Claims lacking approved medical necessity indicators will be denied, and patients may be balance-billed.